BridgeBio CEO-linked trusts sell 80K shares

BridgeBio Pharma, Inc. CEO Neil Kumar reported insider sales executed through family trusts.

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. CEO Neil Kumar reported insider sales executed through family trusts. Trusts associated with him sold a total of 80,000 shares of common stock in open-market transactions on May 7–8, 2026, at weighted average prices generally between about $66 and $69 per share, under a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025. The sales were made by the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, where he serves as co-trustee and disclaims beneficial ownership beyond any pecuniary interest. After these transactions, Kumar still holds 234,451 shares of common stock directly as of May 7, 2026, in addition to substantial indirect trust holdings.

Insider Trade Summary 10b5-1

Net Seller: 80,000 shares

Net Sell 13 txns

Insider Kumar Neil

Role Chief Executive Officer

Sold 80,000 shs ($5.39M)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,973	$66.6505	$931K
Sale	Common Stock	5,077	$67.3455	$342K
Sale	Common Stock	950	$68.3477	$65K
Sale	Common Stock	13,974	$66.6505	$931K
Sale	Common Stock	5,076	$67.3455	$342K
Sale	Common Stock	950	$68.3477	$65K
Sale	Common Stock	11,217	$67.495	$757K
Sale	Common Stock	8,333	$68.3775	$570K
Sale	Common Stock	450	$69.0911	$31K
Sale	Common Stock	11,217	$67.4949	$757K
Sale	Common Stock	8,334	$68.3775	$570K
Sale	Common Stock	449	$69.0911	$31K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 555,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 4,358,447 shares (Indirect, By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 234,451 shares (Direct)

Footnotes (8)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
2. F2. Represents the weighted average sale price of the shares sold from $67.02 to $68.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3. F3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
4. F4. Represents the weighted average sale price of the shares sold from $68.02 to $69.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
5. F5. Represents the weighted average sale price of the shares sold from $69.02 to $69.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
6. F6. Represents the weighted average sale price of the shares sold from $66.10 to $67.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
7. F7. Represents the weighted average sale price of the shares sold from $67.10 to $68.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
8. F8. Represents the weighted average sale price of the shares sold from $68.17 to $68.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Key Figures

Shares sold: 80,000 shares Representative sale price: $69.0911 per share Sale price range: About $66–$69 per share +3 more

6 metrics

Shares sold 80,000 shares Net open-market sales reported on May 7–8, 2026

Representative sale price $69.0911 per share One open-market sale of 449–450 shares on May 7, 2026

Sale price range About $66–$69 per share Weighted average price ranges described in footnotes F2–F8

Direct holdings after trades 234,451 shares Common stock held directly as of May 7, 2026

Rule 10b5-1 plan adoption date March 31, 2025 Plan governing the reported sales

Sale transactions count 12 transactions Non-derivative open-market sales in this Form 4

Key Terms

Rule 10b5-1 sales plan, weighted average sale price, beneficial ownership, pecuniary interest, +1 more

5 terms

Rule 10b5-1 sales plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."

weighted average sale price financial

"Represents the weighted average sale price of the shares sold from $67.02 to $68.01 per share."

beneficial ownership regulatory

"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any,"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission"

Section 16 regulatory

"shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

FAQ

What did BridgeBio Pharma (BBIO) CEO Neil Kumar report in this Form 4?

Neil Kumar reported pre-planned insider sales of BridgeBio Pharma common stock through family trusts. The transactions were open-market sales executed under a Rule 10b5-1 plan, with detailed share counts, prices, and post-transaction holdings disclosed for transparency.

How many BridgeBio Pharma (BBIO) shares were sold in these insider transactions?

Entities associated with Neil Kumar sold a total of 80,000 BridgeBio Pharma common shares. The sales were split across multiple open-market trades on May 7–8, 2026, as summarized in the filing’s transaction data and reflected in the net-sell share count disclosed.

At what prices were the BridgeBio Pharma (BBIO) shares sold by the trusts?

The shares were sold at weighted average prices generally between about $66 and $69 per share. Footnotes specify price ranges for each group of trades and state that detailed per-trade pricing information is available upon request from specified parties.

Were Neil Kumar’s BridgeBio Pharma (BBIO) share sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were executed pursuant to a Rule 10b5-1 sales plan adopted on March 31, 2025. Such pre-arranged plans automate trades under preset conditions, providing structure and reducing the significance of trade timing decisions.

Does Neil Kumar still hold BridgeBio Pharma (BBIO) shares after these sales?

Yes. The filing shows he holds 234,451 shares of BridgeBio common stock directly as of May 7, 2026. It also reports large additional indirect holdings through the Kumar Haldea Revocable Trust and Kumar Haldea Family Irrevocable Trust, where he serves as co-trustee.

Were the BridgeBio Pharma (BBIO) shares sold directly by Neil Kumar or through trusts?

The reported sales were made by the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust. Neil Kumar is a co-trustee of these entities and disclaims beneficial ownership of the shares except to the extent of any pecuniary interest he may have.

What does the beneficial ownership disclaimer mean in Neil Kumar’s BridgeBio (BBIO) filing?

The filing states Neil Kumar disclaims beneficial ownership of the trust-held shares beyond any pecuniary interest. This means he does not concede full beneficial ownership for regulatory purposes, even though he is a co-trustee and the transactions are reported in his Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		S(1)		11,217	D	$67.495(2)	584,469	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/07/2026		S(1)		8,333	D	$68.3775(4)	576,136	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/07/2026		S(1)		450	D	$69.0911(5)	575,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/07/2026		S(1)		11,217	D	$67.4949(2)	4,387,230	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/07/2026		S(1)		8,334	D	$68.3775(4)	4,378,896	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/07/2026		S(1)		449	D	$69.0911(5)	4,378,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/08/2026		S(1)		13,973	D	$66.6505(6)	561,713	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/08/2026		S(1)		5,077	D	$67.3455(7)	556,636	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/08/2026		S(1)		950	D	$68.3477(8)	555,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/08/2026		S(1)		13,974	D	$66.6505(6)	4,364,473	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/08/2026		S(1)		5,076	D	$67.3455(7)	4,359,397	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock	05/08/2026		S(1)		950	D	$68.3477(8)	4,358,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock								234,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $67.02 to $68.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. Represents the weighted average sale price of the shares sold from $68.02 to $69.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. Represents the weighted average sale price of the shares sold from $69.02 to $69.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

6. Represents the weighted average sale price of the shares sold from $66.10 to $67.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

7. Represents the weighted average sale price of the shares sold from $67.10 to $68.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

8. Represents the weighted average sale price of the shares sold from $68.17 to $68.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)